Regenxbio (RGNX) Current Deferred Revenue (2014 - 2026)
Regenxbio (RGNX) posted quarterly Current Deferred Revenue of $29.4 million for Q4 2025, up 25465.22% year-over-year from N/an in Q4 2024, and up 122.81% quarter-over-quarter from $13.2 million in Q3 2025.
Regenxbio (RGNX) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Regenxbio's Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $29.4 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 25465.22% year-over-year to $29.4 million; the TTM figure through Dec 2025 stood at $29.4 million (up 25465.22% YoY), while the FY2025 annual figure was $29.4 million, up 25465.22% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $29.4 million, up from $13.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $39.9 million in Q1 2025, with the low at $13000.0 in Q1 2024.
- The 5-year median for Current Deferred Revenue is $3.3 million (2021), against an average of $7.8 million.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 99.01% in 2024, then jumped 306707.69% in 2025.
- Regenxbio's Current Deferred Revenue stood at $3.3 million in 2021, then plunged by 45.12% to $1.8 million in 2022, then tumbled by 91.91% to $148000.0 in 2023, then dropped by 22.3% to $115000.0 in 2024, then jumped by 25465.22% to $29.4 million in 2025.
- Business Quant data shows RGNX's Current Deferred Revenue at $29.4 million in Q4 2025, $13.2 million in Q3 2025, and $37.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.30 Mn |
| Dec 31, 2025 | 29.40 Mn |
| Sep 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 37.78 Mn |
| Mar 31, 2025 | 39.89 Mn |
| Dec 31, 2024 | 115,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 448,000.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 3.33 Mn |
| Sep 30, 2021 | 3.93 Mn |
| Jun 30, 2021 | 4.03 Mn |